4/23/2024 | CV | Market Commentary: Barclays synthetic, Vertex convertible offerings play to strong demand; Xerox drops
|
4/23/2024 | CV | Market Commentary: Morning Commentary: Barclays synthetic, Vertex convertible notes offerings in focus
|
4/22/2024 | CV | Market Commentary: Convertibles primary breaks silence; Vertex, Barclays synthetic on tap; Wolfspeed surges
|
4/22/2024 | CVSP | Barclays to sell $350 million cash-settled equity-linked notes tied to Eli Lilly at 0.25%, up 31%
|
2/21/2024 | SP | Market Commentary: Citi’s $11 million autocalls on Nasdaq-100 imply possible opportunity cost, volatility risk
|
2/7/2024 | IG | New Issue: Eli Lilly prices $6.5 billion of senior notes in five tranches
|
2/7/2024 | GNIG | S&P assigns A+ to Eli Lilly notes
|
2/7/2024 | IG | Eli Lilly readies five-part note offering via five bookrunners
|
2/7/2024 | GNIG | Moody’s rates Eli Lilly notes A1
|
10/31/2023 | SP | New Issue: UBS prices $2.09 million contingent income autocallable securities on Eli Lilly
|
10/19/2023 | SP | New Issue: UBS prices $7.67 million contingent income autocallable securities on Eli Lilly
|
10/17/2023 | SP | New Issue: Barclays sells $2.65 million phoenix autocallable notes on Apple, Visa, Eli Lilly
|
10/16/2023 | SP | New Issue: Barclays sells $4.13 million trigger autocallable contingent yield notes on Eli Lilly
|
10/13/2023 | SP | New Issue: Barclays sells $1.15 million phoenix autocallable notes on Eli Lilly, Apple, Visa
|
9/21/2023 | SP | New Issue: UBS prices $4.44 million contingent income autocallable securities on Eli Lilly
|
7/21/2023 | SP | New Issue: UBS prices $4.63 million contingent income autocallable securities on Eli Lilly
|
6/28/2023 | SP | New Issue: JPMorgan prices $1.58 million return notes linked to basket of 20 stocks
|
6/6/2023 | SP | New Issue: Morgan Stanley prices $3.09 million contingent income autocalls on three stocks
|
6/6/2023 | SP | New Issue: Morgan Stanley prices $4.88 million contingent income autocalls on three stocks
|
3/15/2023 | SP | New Issue: JPMorgan sells $1 million autocallable contingent interest notes on Eli Lilly
|
2/24/2023 | IG | Market Commentary: IG bond supply slows ahead of expected pickup; fund inflows decline; ETF inflows up
|
2/23/2023 | IG | New Issue: Eli Lilly prices $4 billion of senior notes in four tranches
|
2/23/2023 | GNIG | S&P assigns A+ to Eli Lilly notes
|
2/23/2023 | IG | Eli Lilly readies four-part note offering via four bookrunners
|
2/16/2023 | SP | New Issue: Morgan Stanley prices $1.17 million 8.4% callable fixed income securities on Eli Lilly
|
1/19/2023 | SP | New Issue: JPMorgan sells $3.51 million trigger autocallable contingent yield notes on Eli Lilly
|
12/5/2022 | GNIG | Moody’s alters Lilly view to positive
|
11/17/2022 | SP | New Issue: BMO sells $1.2 million autocallable barrier notes with contingent coupon on Eli Lilly
|
10/24/2022 | SP | New Issue: HSBC prices $1.44 million phoenix quarterly review notes with memory on Eli Lilly
|
6/9/2022 | SP | New Issue: UBS prices $5.24 million contingent income autocalls on three stocks
|
5/12/2022 | SP | New Issue: UBS prices $1.72 million phoenix autocallable notes with memory coupon on Eli Lilly
|
4/27/2022 | SP | New Issue: RBC prices $665,000 trigger autocallable contingent yield notes on Eli Lilly
|
2/15/2022 | SP | New Issue: UBS prices $2.18 million phoenix autocallable notes with memory coupon on Eli Lilly
|
2/11/2022 | SP | Market Commentary: HSBC’s $250,000 phoenix autocalls on Eli Lilly provide risk mitigation with memory feature
|
2/11/2022 | SP | New Issue: HSBC prices $250,000 phoenix quarterly review notes with memory on Eli Lilly
|
2/7/2022 | GNIG | S&P shifts Eli Lilly view to stable
|
1/31/2022 | EULM | Eli Lilly to redeem €600 million 1% notes due 2022 on March 2
|
12/29/2021 | SP | New Issue: UBS sells $2.67 million 7.45% airbag autocallable yield notes on Eli Lilly
|
11/24/2021 | SP | New Issue: Credit Suisse sells $4.45 million 8.75% autocallable reverse convertibles on four stocks
|
10/18/2021 | SP | New Issue: JPMorgan sells $6.11 million review notes tied to three stocks
|
9/8/2021 | GN | New Issue: Eli Lilly prices €600 million 0.5% sustainability notes due 2033
|
9/8/2021 | GNIG | Moody's rates Eli Lilly's notes A2
|
9/8/2021 | GNIG | S&P gives A+ to Eli Lilly notes
|
9/7/2021 | GN | Eli Lilly plans euro-denominated sustainability notes offering
|
9/1/2021 | SP | New Issue: HSBC prices $10 million phoenix monthly review notes with memory on Eli Lilly
|
8/20/2021 | SP | New Issue: HSBC sells $2.4 million autocallable barrier notes with step-up premium on four stocks
|
7/28/2021 | SP | New Issue: CIBC sells $2.35 million contingent coupon autocallable barrier notes on three stocks
|
6/30/2021 | SP | New Issue: HSBC prices $10 million phoenix monthly review notes with memory on Eli Lilly
|
12/17/2020 | SP | New Issue: HSBC sells $2.25 million autocallable barrier notes with step-up premium on stocks
|
8/21/2020 | IG | Market Commentary: High-grade supply remains strong; lighter action eyed to close out August; new issues mixed
|
8/21/2020 | IG | Market Commentary: Morning Commentary: Investment-grade supply quiets after strong week; new issues mixed
|
8/20/2020 | EMHYPFPV | Market Commentary: Johnson & Johnson, Eli Lilly, Principal Life, IFC price notes; high-grade inflows decline
|
8/20/2020 | IG | Market Commentary: Johnson & Johnson, Eli Lilly, Principal Life, IFC price notes; high-grade inflows decline
|
8/20/2020 | IG | S&P gives Eli Lilly notes A+
|
8/20/2020 | IG | New Issue: Eli Lilly prices $1.1 billion of senior notes in new, reopened tranches
|
8/20/2020 | IG | S&P gives Eli Lilly notes A+
|
8/20/2020 | IG | Market Commentary: Morning Commentary: Johnson & Johnson, Eli Lilly, Principal Life, IFC to price notes
|
4/24/2020 | EMHYPFPV | Market Commentary: Eli Lilly, Texas Instruments, Fairfax price; Biogen, Delta Air on tap
|
4/24/2020 | IG | Market Commentary: Eli Lilly, Texas Instruments, Fairfax price; Biogen, Delta Air on tap; bank paper improves
|
4/24/2020 | IG | New Issue: Eli Lilly prices $1 billion 2.25% 30-year senior notes at 110 bps over Treasuries
|
4/24/2020 | IG | Market Commentary: Morning Commentary: High-grade issuers Eli Lilly, Texas Instruments in Friday pipeline
|
4/24/2020 | IG | S&P rates Eli Lilly notes A+
|
4/24/2020 | IG | Eli Lilly plans to sell fixed-rate notes via four bookrunners
|
3/3/2020 | IG | S&P trims General Dynamics
|
3/3/2020 | IG | S&P shifts Eli Lilly view to negative
|
6/27/2019 | SP | New Issue: RBC sells $3.22 million contingent coupon barrier autocalls on three stocks
|
6/20/2019 | SP | JPMorgan to price capped return enhanced notes linked to Eli Lilly
|
4/23/2019 | SP | Morgan Stanley to price trigger autocallables linked to Eli Lilly
|
3/22/2019 | SP | HSBC plans Income Plus CDs due 2024 on stocks with 8% potential coupon
|
3/22/2019 | SP | HSBC plans Income Plus CDs due 2024 on stocks with 5% potential coupon
|
2/20/2019 | EMHYPFPV | Market Commentary: Eli Lilly, Prudential, Whirlpool, CBS, Hudson, KfW, BNG, Council of Europe tap primary
|
2/20/2019 | IG | Market Commentary: Eli Lilly, Prudential, Whirlpool, CBS, Hudson, KfW, BNG, Council of Europe tap primary
|
2/20/2019 | IG | New Issue: Eli Lilly prices $4.5 billion of senior notes in four tranches
|
2/20/2019 | IG | S&P rates Eli Lilly notes A+
|
2/20/2019 | IG | Eli Lilly plans to price fixed-rate notes in four tranches
|
2/19/2019 | IG | S&P lowers Eli Lilly
|
2/15/2019 | SP | HSBC plans Income Plus CDs due 2022 on stocks with 5% potential coupon
|
2/15/2019 | SP | HSBC plans Income Plus CDs due 2024 on stocks with 8% potential coupon
|
2/15/2019 | SP | HSBC plans Income Plus CDs due 2024 on stocks with 5% potential coupon
|
2/15/2019 | SP | HSBC plans Income Plus CDs due 2022 on stocks with 6% potential coupon
|
1/23/2019 | SP | HSBC plans Income Plus CDs due 2024 on stocks with 8% potential coupon
|
1/23/2019 | SP | HSBC plans Income Plus CDs due 2024 on stocks with 5% potential coupon
|
1/23/2019 | SP | HSBC plans income plus CDs on five stocks with 1.05% minimum coupon
|
1/8/2019 | IG | S&P puts Eli Lilly on negative watch
|
9/21/2018 | SP | New Issue: RBC sells $1.55 million 9.3% contingent coupon autocalls tied to three stocks
|
9/11/2018 | SP | New Issue: RBC sells $4.78 million contingent coupon barrier autocalls on three stocks
|
8/22/2018 | SP | RBC plans 9.1%-10.1% contingent coupon autocalls on biotech, pharma
|
3/19/2018 | SP | HSBC plans five-year Rate Builder CDs linked to Safety Rank 1 stocks
|
2/8/2018 | SP | HSBC plans five-year Rate Builder CDs linked to Safety Rank 1 stocks
|
12/11/2017 | SP | HSBC plans five-year Rate Builder CDs linked to Safety Rank 1 stocks
|
6/12/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 9.75% potential coupon
|
6/12/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 8.25% potential coupon
|
6/12/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 6.75% potential coupon
|
6/12/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 5.25% potential coupon
|
6/12/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 7.5% potential coupon
|
6/12/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 6% potential coupon
|
6/12/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 4.5% potential coupon
|
6/12/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 3.25% potential coupon
|
5/8/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 9.75% potential coupon
|
5/8/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 8.25% potential coupon
|
5/8/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 6.75% potential coupon
|
5/8/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 5.25% potential coupon
|
5/8/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 7.75% potential coupon
|
5/8/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 6.25% potential coupon
|
5/8/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 4.75% potential coupon
|
5/8/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 3.5% potential coupon
|
5/8/2017 | SP | HSBC to price autocallable accumulating income CDs linked to stocks
|
5/4/2017 | EMHYPFPV | Market Commentary: Apple, Eli Lilly, General Motors Financial, EnLink tap primary market; Apple notes soften
|
5/4/2017 | IG | Market Commentary: Apple, Eli Lilly, General Motors Financial, EnLink tap primary market; Apple notes soften
|
5/4/2017 | IG | Fitch rates Eli Lilly notes A
|
5/4/2017 | IG | S&P rates Eli Lilly notes AA-
|
5/4/2017 | IG | New Issue: Eli Lilly prices $2.25 billion of fixed-rate notes in three tranches
|
5/4/2017 | IG | Moody’s rates Eli Lilly notes A2
|
5/4/2017 | IG | Eli Lilly intends to price fixed-rate notes in three tranches
|
4/17/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 7.75% potential coupon
|
4/17/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 6.25% potential coupon
|
4/17/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 4.75% potential coupon
|
4/17/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 3.5% potential coupon
|
4/17/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 9.75% potential coupon
|
4/17/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 8.25% potential coupon
|
4/17/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 6.75% potential coupon
|
4/17/2017 | SP | HSBC plans Income Plus CDs tied to stocks with 5.25% potential coupon
|
3/8/2017 | SP | New Issue: HSBC prices $1.6 million autocallable contingent income barrier notes on stocks
|
12/28/2016 | SP | New Issue: HSBC prices $5 million five-year income plus notes linked to five stocks
|
12/23/2016 | SP | New Issue: HSBC prices $733,000 seven-year income plus notes linked to five stocks
|
12/6/2016 | SP | HSBC plans income plus notes tied to five stocks with 1%-8.5% coupon
|
11/23/2016 | IG | Moody’s: Eli Lilly drug failure is credit negative
|
11/21/2016 | SP | Barclays to price Accelerated Return Notes linked to seven stocks
|
11/7/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
11/7/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
11/2/2016 | SP | HSBC plans income plus notes on five stocks with 5.5% potential coupon
|
11/2/2016 | SP | HSBC plans income plus notes on five stocks with 8% potential coupon
|
11/1/2016 | SP | New Issue: HSBC prices $1.13 million seven-year income plus notes on five stocks
|
11/1/2016 | SP | New Issue: HSBC prices $292,000 seven-year income plus notes linked to five stocks
|
10/14/2016 | SP | HSBC plans income plus notes on five stocks with 5% potential coupon
|
10/14/2016 | SP | HSBC eyes income plus notes on five stocks with 7.5% potential coupon
|
10/12/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
10/12/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
10/12/2016 | SP | Goldman Sachs plans variable coupon CDs due 2026 linked to 10 stocks
|
10/12/2016 | SP | Goldman Sachs to price variable coupon CDs due 2023 tied to 10 stocks
|
10/10/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
10/10/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
10/7/2016 | SP | New Issue: HSBC prices $5.49 million income notes linked to 20 stocks
|
10/5/2016 | IG | Moody’s: Eli Lilly unaffected by acquisition
|
9/13/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 tied to 10 stocks
|
9/13/2016 | SP | Goldman Sachs plans variable coupon CDs due 2026 linked to 10 stocks
|
9/13/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
9/13/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
9/12/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
9/12/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
9/12/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 4.25% potential coupon
|
9/12/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 5.5% potential coupon
|
9/12/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 3% potential coupon
|
9/12/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 4.5% potential coupon
|
9/12/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 3.25% potential coupon
|
9/12/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 2% potential coupon
|
9/12/2016 | SP | New Issue: RBC prices $2.84 million contingent coupon barrier autocallables linked to Eli Lilly, Southwest
|
9/6/2016 | SP | New Issue: RBC prices $2 million contingent coupon barrier autocallables tied to two stocks
|
8/30/2016 | SP | New Issue: HSBC prices $2.54 million income notes linked to 20 stocks
|
8/30/2016 | SP | New Issue: Barclays sells $2.16 million phoenix autocallable notes on three stocks
|
8/23/2016 | SP | New Issue: JPMorgan prices $5.29 million contingent interest autocallables linked to four stocks
|
8/9/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
8/9/2016 | SP | Goldman Sachs plans variable coupon CDs due 2026 linked to 10 stocks
|
8/9/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
8/9/2016 | SP | Goldman Sachs plans to price variable coupon CDs linked to 10 stocks
|
8/8/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
8/8/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
8/8/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 5.5% potential coupon
|
8/8/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 4.25% potential coupon
|
8/8/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 3% potential coupon
|
8/8/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 4.5% potential coupon
|
8/8/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 3.25% potential coupon
|
8/8/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 2% potential coupon
|
7/19/2016 | SP | New Issue: JPMorgan prices $3.17 million contingent income autocallables linked to Eli Lilly
|
7/11/2016 | SP | Goldman Sachs plans to price variable coupon CDs linked to 10 stocks
|
7/11/2016 | SP | Goldman Sachs plans variable coupon CDs due 2026 linked to 10 stocks
|
7/11/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
7/11/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
7/11/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 5.25% potential coupon
|
7/11/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 2.25% potential coupon
|
7/11/2016 | SP | HSBC plans Income Plus CDs tied to stocks with 4.25% potential coupon
|
7/11/2016 | SP | HSBC plans Income Plus CDs linked to stocks with 3% potential coupon
|
7/11/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
7/11/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
7/11/2016 | SP | JPMorgan plans contingent income autocallables linked to Eli Lilly
|
6/13/2016 | SP | HSBC plans to price seven-year Rate Builder CDs linked to 10 stocks
|
6/13/2016 | SP | HSBC plans to price five-year Rate Builder CDs linked to 10 stocks
|
5/27/2016 | SP | New Issue: RBC prices $1.56 million trigger phoenix autocallables on two stocks
|
5/10/2016 | IG | Fitch rates Eli Lilly bond A
|
5/10/2016 | IG | Moody’s assigns A2 to Eli Lilly notes
|
5/10/2016 | SP | HSBC plans 0.25%-3.5% five-year Rate Builder CDs linked to 10 stocks
|
5/10/2016 | SP | HSBC plans 0.3%-5% seven-year Rate Builder CDs linked to 10 stocks
|
5/10/2016 | IG | S&P rates Eli Lilly bond AA-
|
4/11/2016 | SP | Goldman Sachs to price variable coupon CDs linked to stock basket
|
4/11/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
4/11/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
3/10/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
3/10/2016 | SP | Goldman Sachs to price variable coupon CDs tied to 10 stocks
|
3/10/2016 | SP | Goldman Sachs plans to price variable coupon CDs linked to 10 stocks
|
2/18/2016 | SP | New Issue: Credit Suisse prices $1.56 million 8.5% airbag autocallables linked to Eli Lilly
|
2/9/2016 | SP | Credit Suisse plans 6.4%-8.4% airbag autocallables linked to Eli Lilly
|
2/9/2016 | SP | Goldman Sachs plans to price variable coupon CDs linked to 10 stocks
|
2/9/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
2/9/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
1/14/2016 | SP | Goldman Sachs plans variable coupon CDs due 2023 linked to 10 stocks
|
1/14/2016 | SP | Goldman Sachs plans variable coupon CDs due 2021 linked to 10 stocks
|
12/31/2015 | LM | Market Commentary: Outlook 2016: AIG, KazMunay Gas, Hewlett-Packard in big deals; commodity pricing has impact
|
11/9/2015 | SP | New Issue: RBC prices $1.2 million trigger phoenix autocallables on Bristol-Myers, Eli Lilly
|
10/26/2015 | SP | New Issue: Morgan Stanley prices $3.36 million contingent coupon notes linked to 10 stocks
|
10/15/2015 | SP | Goldman Sachs plans variable coupon CDs due 2022 linked to 10 stocks
|
10/15/2015 | SP | Goldman Sachs plans variable coupon CDs due 2020 linked to 10 stocks
|
5/28/2015 | IGLM | Eli Lilly gets early tenders for $1.45 billion of notes; pricing set
|
5/26/2015 | IG | S&P rates Eli Lilly bond AA-
|
5/26/2015 | IG | Fitch: Eli Lilly euro notes A
|
5/26/2015 | IG | Moody’s applies A2 to Eli Lilly euro notes
|
5/12/2015 | IGLM | Eli Lilly tenders for up to $1.6 billion of bonds, calls 6.57% notes
|
2/27/2015 | IG | Market Commentary: Morning Commentary: Juniper Networks notes tighten, Eli Lilly improves in early trade
|
2/26/2015 | IG | Market Commentary: Morning Commentary: Chevron, Eli Lilly senior notes firm 4 bps to 5 bps in secondary trading
|
2/24/2015 | EMHYMUPFPV | Market Commentary: Busy primary sees Chevron, Eli Lilly, Kimberly-Clark price; AT&T firms; Southwestern mixed
|
2/24/2015 | IG | Market Commentary: Busy primary sees Chevron, Eli Lilly, Kimberly-Clark do deals; AT&T firms; Southwestern mixed
|
2/24/2015 | IG | New Issue: Eli Lilly prices $2.2 billion of notes in three tranches
|
2/24/2015 | IG | Fitch rates Eli Lilly notes A
|
2/24/2015 | IG | Moody's rates Eli Lilly notes A2
|
2/24/2015 | IG | S&P assigns Eli Lilly notes AA-
|
2/24/2015 | IG | Eli Lilly plans benchmark three-part notes offering
|
9/2/2014 | SP | HSBC plans income plus notes on stock basket with 1% minimum coupon
|
7/9/2014 | SP | JPMorgan plans to price return notes linked to basket of 16 stocks
|
4/24/2014 | IG | Fitch affirms Eli Lilly on acquisition news
|
4/22/2014 | IG | Moody's affirms Eli Lilly
|
2/24/2014 | IG | Market Commentary: Midday Commentary: Investment-grade bonds stable; Eli Lilly notes firm; Google trades flat
|
2/21/2014 | IG | Fitch rates Eli Lilly notes A
|
2/20/2014 | IG | Moody's assigns Eli Lilly notes A2
|
2/20/2014 | IG | Market Commentary: Canada, Google, Whirlpool deals price tight; Eli Lilly joins primary; Google eases, then firms
|
2/20/2014 | IG | Eli Lilly plans $800 million two-part notes in five-, 30-year tranches
|
2/20/2014 | IG | New Issue: Eli Lilly prices upsized $1 billion issue in five-, 30-year tranches
|
2/20/2014 | IG | S&P rates Eli Lilly notes AA-
|
10/31/2012 | SP | New Issue: HSBC prices $1.18 million income plus notes on five stocks with 1% minimum coupon
|
11/3/2011 | IG | Fitch downgrades Eli Lilly
|
6/10/2011 | SP | New Issue: HSBC prices $3 million income plus notes linked to basket of five stocks
|
11/8/2010 | IG | Moody's cuts Eli Lilly
|
11/3/2010 | IG | Fitch affirms Eli Lilly
|
10/20/2010 | IG | Moody's may cut Eli Lilly
|
8/19/2010 | IG | S&P cuts Eli Lilly
|
5/21/2010 | IG | Moody's: Eli Lilly outlook negative
|
2/26/2010 | CVIG | Eli Lilly files automatic shelf covering debt, stock and preferreds
|
11/13/2009 | IG | Fitch cuts Eli Lilly outlook to negative
|
10/21/2009 | IG | Market Commentary: Westpac, BB&T price deals, primary watches earnings; spreads tighten; JPMorgan preferreds gain
|
7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|
6/5/2009 | SS | Market Commentary: Icahn burrows into Amylin, Biogen; NRG sets date for Exelon clash; Cougar buyout on track
|
5/27/2009 | SS | Market Commentary: Amylin gives up two board seats; AOL spinoff buzz increases; Cougar lacks counter bids
|
5/1/2009 | SS | Market Commentary: Amylin readies for proxy fight; Exelon should offer NRG more to save face, analyst says
|
4/23/2009 | SS | Market Commentary: Centennial buyout could let AT&T walk; Emulex auction expected; major pharma mergers predicted
|
4/22/2009 | SS | Market Commentary: Omnicare buyout rumors persist; analyst: abrupt Amylin sale unlikely; researchers drop Asyst
|
4/21/2009 | SS | Icahn clarifies statements made to Amylin lead director, chairman
|
4/20/2009 | SS | Amylin lead director accused of mischaracterizing Icahn's comments
|
3/31/2009 | SS | Market Commentary: IPC likely to stick with Max; Agrium may up CF bid to $85/share; Lilly, Amylin combo a distant dream
|
3/17/2009 | IG | Market Commentary: Pfizer sells $13.5 billion bond issue; State Street, SoCal Edison price; Pfizer bonds tighten
|
3/17/2009 | IG | Market Commentary: Pfizer sells $13.5 billion bond issue; State Street, SoCal Edison price; Pfizer bonds tighten
|
3/6/2009 | IG | Market Commentary: Sour tone leaves primary market dry; secondary focuses on financials, FDIC-backed deals most traded
|
3/4/2009 | IG | Market Commentary: Pace slows, Appalachian power, NiSource Finance sell bonds; GE Capital wider on rating worries; Coke, Lilly gain
|
3/3/2009 | IG | Fitch gives Eli Lilly notes A+
|
3/3/2009 | IG | Market Commentary: Eli Lilly, Coca-Cola, PG&E, KfW, Cargill, State Street, Mississippi Power price; Lilly tightens, GE Capital weaker
|
3/3/2009 | IG | New Issue: Eli Lilly sells $2.4 billion notes in three tranches
|
3/3/2009 | IG | S&P assigns Eli Lilly notes AA
|
3/3/2009 | IG | Moody's rates Eli Lilly notes A1
|
2/2/2009 | SS | Market Commentary: Second Amylin shareholder wants changes; analysts predict higher bid for CV Therapeutics
|
11/24/2008 | IG | Fitch lowers Eli Lilly
|
11/24/2008 | SS | Eli Lilly acquires ImClone for $70 per share
|
11/24/2008 | SS | Market Commentary: Citi rescue sparks rally; King takes Alpharma for $37 a share; J&J to buy Omrix; LandAmerica sinks
|
11/21/2008 | IG | Moody's downgrades Lilly
|
11/21/2008 | SS | ImClone shareholders tender 95.5% of outstanding shares in Eli Lilly offer; merger could close Monday
|
11/17/2008 | SS | ImClone, Eli Lilly merger gets nod from German regulator
|
11/6/2008 | SS | Primecap Management reports stake of 5.06% in Eli Lilly
|
11/5/2008 | SS | Merger of ImClone Systems, Eli Lilly clears waiting period hurdle
|
11/4/2008 | SS | Market Commentary: Amylin plunges 25.79%; Elliot cuts Epicor bid to $7.50; Merrill sets vote for Bank of America merger
|
10/21/2008 | IG | S&P: Eli Lilly unaffected
|
10/14/2008 | SS | Eli Lilly begins tender offer for ImClone
|
10/13/2008 | SS | Market Commentary: Morgan Stanley, Wachovia jump as deals okayed; Vishay, Waste Management, United Tech drop bids
|
10/6/2008 | SS | Eli Lilly to buy ImClone for $6.5 billion; Bristol-Myers Squibb to benefit
|
10/6/2008 | SS | Market Commentary: Wachovia war hits the courts but short truce declared; International Rectifier rebuffs Vishay
|
10/6/2008 | IG | S&P: Eli Lilly unchanged
|
10/6/2008 | IG | Moody's may cut Eli Lilly
|
10/6/2008 | IG | Fitch: Eli Lilly on watch
|
10/1/2008 | SS | Market Commentary: Financials up ahead of vote; NatCity leads regionals; Eli Lilly revealed as ImClone's secret bidder
|
10/1/2008 | IG | Fitch affirms Eli Lilly
|
8/21/2008 | SS | Eli Lilly acquires SGX Pharmaceuticals
|
8/20/2008 | SS | Market Commentary: ArecelorMittal digs new steel deal; Eli Lilly sprouts new hormone division; Circuit City still searching
|
8/4/2008 | SS | Lilly firm on $3-per-share offer for SGX Pharmaceuticals
|
7/30/2008 | SS | OrbiMed opposed to Eli Lilly offer for SGX Pharmaceuticals
|
7/14/2008 | SS | SGX shareholder seeks alternatives to acquisition of company by Eli Lilly
|
7/8/2008 | SS | Eli Lilly, SGX Pharmaceuticals to combine in deal valued at $64 million
|
4/23/2008 | IG | Moody's rates Lilly's notes Aa3
|
11/28/2007 | SP | New Issue: Barclays prices $2 million 8.75% reverse convertibles linked to Eli Lilly
|
11/8/2007 | SP | Barclays to price 8.75% reverse convertibles linked to Eli Lilly
|
9/26/2007 | IG | Fitch affirms Lilly
|
12/18/2006 | SS | Biomet, Icos merger deals spur action in Telik; Harrah's bets cagey; Caremark rival bid pushes Medco up
|
10/24/2006 | BT | Lilly kept at peer perform by Bear Stearns
|
10/18/2006 | BT | Fitch affirms Eli Lilly
|
10/18/2006 | BT | Eli Lilly at peer perform by Bear Stearns
|
10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/17/2006 | BT | S&P: Eli Lilly unchanged
|
10/17/2006 | BT | Moody's rates Eli Lilly loan Aa3
|
9/21/2006 | BT | Lilly, Amylin get recommendation from EMEA for diabetes treatment exenatide
|
9/19/2006 | BT | Fitch affirms Eli Lilly
|
9/14/2006 | BT | Eli Lilly, Amylin: exenatide as effective as NovoMix30 in controlling blood sugar
|
8/18/2006 | BT | Eli Lilly's Arxxant gets FDA approvable letter; more data sought
|
8/7/2006 | BT | Market Commentary: Encysive sinks on dilution worries; Acorda higher; Genitope gains; Ariad off
|
7/21/2006 | BT | Lilly reports second-quarter sales of $3.87 billion, up 5% from prior-year period
|
7/21/2006 | BT | Market Commentary: Amgen stronger; ReGen cheered; Cleveland BioLabs debuts lower; Amylin, Nektar weaker
|
7/21/2006 | BT | Lilly, Alcon sign marketing deal for diabetic retinopathy drug candidate Arxxant
|
7/17/2006 | BT | Eli Lilly's Gemzar approved for use with carboplatin in treatment of recurrent ovarian cancer
|
7/14/2006 | BT | Daiichi, Lilly sign European agreement for osteoporosis drug Evista
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
6/12/2006 | BT | Eli Lilly: Ruboxistaurin demonstrates promise in reducing vision loss caused by diabetes
|
6/12/2006 | BT | Eli Lilly, Alkermes say inhaled insulin studies yield promising results
|
6/12/2006 | BT | Amylin, Eli Lilly: Byetta shown to reduce blood glucose levels when added to patients using thiazolidinedione
|
6/12/2006 | BT | Amylin, Lilly and Alkermes: study shows Byetta helps achieve glucose control in type 2 diabetes
|
6/12/2006 | BT | Amylin, Lilly: Two-year study shows Byetta sustains blood glucose control
|
6/5/2006 | BT | Eli Lilly releases positive data on Alimta for lung cancer, gene expression patterns
|
6/5/2006 | BT | Eli Lilly shows positive phase 2 results for breast-cancer treatment Alimta
|
6/5/2006 | BT | Eli Lilly, Alkermes complete enrollment for phase 3 safety study for inhaled insulin
|
5/31/2006 | BT | Eli Lilly launches phase 3 trial of oral cancer agent in non-Hodgkin's lymphoma
|
5/30/2006 | BT | Antares Pharma, Eli Lilly file joint patent application for needle-free injection device
|
5/24/2006 | BT | Eli Lilly study suggests atomoxetine HCI effective in treating ADHD, associated anxiety disorders
|
5/23/2006 | BT | Eli Lilly: Symbyax may improve symptoms of treatment-resistant depression
|
5/22/2006 | BT | Eli Lilly study suggests greater improvement for Symbyax compared to lamotrigine in bipolar depression
|
5/11/2006 | BT | Barr challenging patents protecting Prozac Weekly
|
5/9/2006 | BT | Ariad says Eli Lilly lawsuit revenues 'may be important,' will move AP23573 to phase 3 testing
|
5/9/2006 | BT | Lilly submits Cymbalta application for generalized anxiety disorder
|
5/4/2006 | BT | Ariad, co-plaintiffs awarded more than $65 million in Lilly NF-(kappa)B patent infringement lawsuit
|
4/26/2006 | BT | Federal court orders Eli Lilly to assign intellectual property to Emisphere
|
4/26/2006 | BT | Eli Lilly, Alkermes start phase 3 study for inhaled insulin
|
4/24/2006 | BT | Market Commentary: DOV, Discovery Labs off huge after close; 3 deals emerge; GW up big; Ariad off on Amgen suit
|
4/20/2006 | BT | Eli Lilly says Q1 EPS up 13% to $0.77, sales boosted by Cymbalta growth
|
4/17/2006 | BT | Eli Lilly to seek approval of Evista to treat breast cancer
|
4/12/2006 | BT | Lilly: Study shows Evista does not prevent heart attack
|
3/30/2006 | BT | Eli Lilly at peer perform by Bear Stearns
|
3/24/2006 | BT | Eli Lilly study suggests Cymbalta reduces core anxiety disorder symptoms
|
3/20/2006 | BT | Eli Lilly, Biosite team up on clinical trial using Xigris therapy
|
3/20/2006 | BT | Market Commentary: Boston Life Sciences' stock up as phase 3 trial ends early; BioMarin's stock dips on follow-on stock deal
|
3/14/2006 | BT | Eli Lilly says study shows prasugrel superior in antiplatelet effect to Plavis
|
3/9/2006 | BT | Lilly begins phase 3 trial of enzastaurin to treat brain cancer
|
3/1/2006 | BT | Amylin, Eli Lilly submit supplemental NDA for diabetes drug Byetta
|
2/15/2006 | BT | Eli Lilly, Boehringer Ingelheim change agreements for Yentreve/AriClaim
|
2/14/2006 | BT | Lilly's Cymbalta for diabetic nerve pain found to be safe, well-tolerated
|
2/1/2006 | BT | Lilly begins trials of anti-tumor drug; Isis to receive $750,000 milestone
|
1/9/2006 | BT | Alkermes, Lilly to collaborate on inhaled treatment for osteoporosis
|
12/12/2005 | BT | Lilly's enzastaurin slows progression of lymphoma, study says
|
12/9/2005 | BT | Eli Lilly plans to file supplemental NDA for antidepressant Cymbalta to treat anxiety
|
12/9/2005 | BT | Eli Lilly expects 2006 earnings of up to $3.20 a share, growth that ranks at top for the industry
|
11/22/2005 | BT | Clarient signs deals to provide services to Eli Lilly, license Health Discovery's technology for cancer research
|
11/15/2005 | BT | Amylin Pharmaceuticals, Lilly announce positive results of Byetta for diabetes
|
11/3/2005 | BT | ViroPharma expands deal to buy $4.5 million more in Vancocin from Eli Lilly
|
10/13/2005 | BT | Lilly ICOS joint venture kept at neutral by Merrill
|
9/20/2005 | BT | Lilly maintained by Bear Stearns at peer perform
|
9/14/2005 | BT | Lilly reiterated by Bear Stearns at peer perform
|
9/9/2005 | BT | S&P: Eli Lilly unaffected
|
9/7/2005 | BT | Moody's affirms Eli Lilly, rates notes Aa3
|
9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
8/25/2005 | BT | Fitch rates Eli Lilly notes, loan AA
|
8/4/2005 | BT | Moody's gives Eli Lilly notes Aa3
|
8/4/2005 | BT | Market Commentary: ZymoGenetics follow-on upsized but discounted; Eli Lilly sells $1.5 billion variable floaters
|
8/4/2005 | BT | New Issue: Eli Lilly sells $1.5 billion of variable-rate floaters
|
8/4/2005 | BT | S&P assigns Eli Lilly floaters AA
|
8/3/2005 | BT | Eli Lilly launches $1.5 billion floater, to price Thursday via Merrill, Goldman, Deutsche
|
8/3/2005 | BT | Market Commentary: Lilly launches $1.5 billion floater; Human Genome $230 million convert at bat; MannKind taps PIPEs
|
10/6/2004 | CV | New Issue: ABN Amro sells $2.35 million 9.125% reverse exchangeables linked to Eli Lilly
|
8/11/2004 | CV | New Issue: ABN Amro sells $8.16 million 10% reverse exchangeables linked to Eli Lilly
|